Levothyroxine sodium is a Small Molecule owned by Merck, and is involved in 7 clinical trials, which were completed.

Levothyroxine is a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.

The revenue for Levothyroxine sodium is expected to reach a total of $12.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Levothyroxine sodium NPV Report.

Levothyroxine sodium is currently owned by Merck.

Levothyroxine sodium Overview

Levothyroxine Sodium (Novothyrox, Euthyrox, Eutirox, Levothyrox) is a synthetic form of thyroxine derived from the thyroid gland. It is formulated as tablets for oral route of administration. Levothyroxine Sodium is indicated as therapy of hormone replacement or supplementation in patients with hypothyroidism of any etiology (except for transient hypothyroidism, during the recovery phase of subacute thyroiditis) primary hypothyroidism resulting from functional deficit; primary atrophy of thyroid; total or partial ablation of the thyroid gland, with or without goiter and hypothyroidism secondary (pituitary) or tertiary (hypothalamic).

Merck Overview

Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

The company reported revenues of (Euro) EUR19,687 million for the fiscal year ended December 2021 (FY2021), an increase of 12.3% over FY2020. In FY2021, the company’s operating margin was 21.2%, compared to an operating margin of 17% in FY2020. In FY2021, the company recorded a net margin of 15.5%, compared to a net margin of 11.3% in FY2020. The company reported revenues of EUR5,806 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.

Quick View – Levothyroxine sodium

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Levothyroxine sodium
Administration Pathway
  • Oral
Therapeutic Areas
  • Hormonal Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.